J 2009

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

LUDWIG, Heinz, Roman HÁJEK, Elena TÓTHOVÁ, Johannes DRACH, Zdeněk ADAM et. al.

Basic information

Original name

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

Name in Czech

Srovnání léčby Thalidomid-dexamethason s melphalan-prednison u pacientů s mnohočetným myelomem

Authors

LUDWIG, Heinz (40 Austria), Roman HÁJEK (203 Czech Republic, guarantor), Elena TÓTHOVÁ (703 Slovakia), Johannes DRACH (40 Austria), Zdeněk ADAM (203 Czech Republic), Boris LABAR (191 Croatia), Miklós EGYED (348 Hungary), Ivan ŠPIČKA (203 Czech Republic), Heinz GISSLINGER (40 Austria), Richard GREIL (40 Austria), Ingrid KUHN (40 Austria), Niklas ZOJER (40 Austria) and Axel HINKE (276 Germany)

Edition

Blood, Washington, DC, USA, The American Society of Hematology, 2009, 0006-4971

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 10.555

RIV identification code

RIV/00216224:14110/09:00035390

Organization unit

Faculty of Medicine

UT WoS

000265052300008

Keywords (in Czech)

mnohočetný myelom; thalidomid

Keywords in English

multiple myeloma; thalidomide; dexamethasone; melphalane; prednisone

Tags

dexamethasone, melphalane, multiple myeloma, prednisone, Thalidomide

Tags

International impact, Reviewed
Změněno: 1/4/2010 16:54, Mgr. Anna Potáčová, Ph.D.

Abstract

ORIG CZ

V originále

We compared thalidomide-dexamethasone with melphalan-prednisolone in 289 elderly patients with multiple myeloma. This is the first trial to compare TD with MP in elderly patients. Results in the TD group showed a significantly higher rate of very good responses (CR and VGPR) and significantly shorter time to response with no difference in time to progression and in progression-free survival.

In Czech

V článku je dokumentován výsledek první srovnávací studie léčby thalidomid-dexamethason s léčbou melphalan-prednisone.

Links

LC06027, research and development project
Name: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)
Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group
MSM0021622434, plan (intention)
Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
Displayed: 13/11/2024 10:14